Daejeon City Establishes mRNA·DNA-Based 'New Drug Startup Ecosystem'
[Asia Economy (Daejeon) Reporter Jeong Il-woong] Daejeon City is set to establish a startup ecosystem for new drugs based on mRNA and DNA technologies.
The city announced on the 30th that it has been selected for the Ministry of Trade, Industry and Energy's '2022 Industrial Innovation Infrastructure Construction Project' and will receive 10 billion KRW in national funding.
The project aims to support technological innovation activities of small and medium-sized enterprises by building research and development infrastructure, which is difficult for SMEs and mid-sized companies to establish on their own, at universities and other institutions.
Daejeon, with KAIST as the lead and the city as a collaborator, will focus on establishing industrial innovation infrastructure equipment and supporting companies to accelerate the development of mRNA and DNA-based vaccines and pharmaceuticals. The project will invest a total of 14.3 billion KRW, including 10 billion KRW in national funds and 4.3 billion KRW from the city, through 2026.
Through this project, KAIST will establish equipment related to cultivation, purification, and analysis for the design and production base of mRNA and DNA vaccines and pharmaceuticals. Additionally, it plans to provide customized technical guidance and process technology development support to demand companies for mRNA/DNA pharmaceutical production, including preclinical sample production, test analysis, and production process collaboration.
The city envisions creating a startup ecosystem for new drugs based on mRNA and DNA through this project.
Hot Picks Today
"Buy on Black Monday"... Japan's Nomura Forecasts 590,000 for Samsung, 4 Million for SK hynix
- "Not Everyone Can Afford This: Inside the World of the True Top 0.1% [Luxury World]"
- "Plunged During the War, Now Surging Again"... The Real Reason Behind the 6% One-Day Silver Market Rally [Weekend Money]
- "We're Now Earning 10 Million Won a Month"... Semiconductor Boom Drives Performance Bonuses at Major Electronic Component Firms
- "Target Price Set at 970,000 Won"... Top Investors Already Watching, Only an 'Uptrend' Remains [Weekend Money]
Jung Jae-yong, Director of the Science and Industry Bureau of the city, said, “We will achieve technological competitiveness in the development of mRNA and DNA-based pharmaceuticals in Daejeon to respond to global infectious diseases,” adding, “We will firmly establish ourselves as a central city for bio startups.”
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
